Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 50, Issue 9, Pages 1387-1390Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.109.061838
Keywords
molecular imaging; MRI; PET; SPECT; radiopharmaceutical
Funding
- National Institutes of Health [CA92871, CA134675]
- Prostate Cancer Foundation
- NATIONAL CANCER INSTITUTE [U24CA092871, R24CA092871, R01CA134675] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The successful management of prostate cancer requires early detection, appropriate risk assessment, and optimum treatment. An unmet goal of prostate cancer imaging is to differentiate indolent from aggressive tumors, as treatment may vary for different grades of the disease. Different modalities have been tested to diagnose, stage, and monitor prostate cancer during therapy. This review briefly describes the key clinical issues in prostate cancer imaging and therapy and summarizes the various new imaging modalities and agents in use and on the horizon.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available